Alexander R. Gottschalk, M.D., Ph.D.
- Professor of Radiation Oncology
- Director, CyberKnife Radiosurgery Program
- Department of Radiation Oncology
Contact Information
Box 1708, 1600 Divisadero St, MZ Bldg R H1031
San Francisco, CA. 94143 - 1708
Phone: 415-353-7175
Fax 415-353-9883
[email protected]
Education
1988 University of Chicago BA Chemistry
1994 University of Chicago PhD Pathology
1996 University of Chicago MD Medicine
1996-1997 Kaiser Permanente Medical Center, Santa Clara, CA Intern Internal Medicine
1997-2001 UCSF Resident Radiation Oncology
01/00-04/00 UCSF Chief Resident Radiation Oncology
Residencies
- 1997-2001 UCSF Residency in Radiation Oncology
- 1996-1997 Kaiser Internal Medicine Internship
Biography
Dr. Alexander Gottschalk, an expert in radiation treatment, is director of the UCSF Cyberknife Radiosurgery Program. Using the Cyberknife, Gottschalk treats cancer of the brain and spine; breast, chest and lung; abdomen; kidney; and pelvis. In addition, he treats urologic cancer such as bladder and prostate cancer; gastrointestinal cancer such as pancreas cancer; soft tissue tumors such as sarcoma and thoracic cancer such as lung cancer, using other radiation treatments.
Gottschalk earned a medical degree and Ph.D. at the University of Chicago and completed a residency in radiation oncology at UCSF Medical Center. He is the recipient of numerous awards and grants, including the National Institutes of Health National Research Service Award, Medical Scientist Training Program Fellowship, UCSF Helen Diller Family Comprehensive Cancer Center Clinical Investigator Research Program Grant, the RSNA Scholar award and the ASTRO Junior faculty award. He is an associate professor of radiation oncology at UCSF and active in genitourinary research. He is developing clinical trials using inter-operative.
Awards & Honors
Research Overview
Dr. Gottschalk is involved in a number of clinical research projects. First, he has studied several methods of image-guided radiotherapy (IGRT), including, ultrasound, electronic portal imagining using gold seed fiducial markers and megavoltage cone-beam CT (MVCBCT). His research is one of the first to evaluate prostate bed motion in patients undergoing radiotherapy after prostatectomy. Dr. Gottschalk has investigated the use of MVCBCT for dose calculation and re-calculation as well as a novel high quality, low dose, imaging beam line. The dose re-calculation can be use for dose guided radiation therapy (DGRT).
Second, using the Radiation Oncology clinical database, Dr. Gottschalk has studied: the effectiveness of intraoperative radiation therapy (IORT) in the management of extremity sarcomas and renal cell carcinoma recurrences, permanent seed brachytherapy and high dose-rate brachytherapy (HDR) for the treatment of prostate cancer both as primary therapy and as salvage after radiation failures.
Third, he has been involved as a co-investigator in three trials: a Phase 2, Single-Center, Open-Label phase I/II study to evaluate safety and efficacy and Safety in patients who have resectable esophageal cancer and are treated with neoadjuvant cisplatin, irinotecan (CPT-11), ZD1839 (IRESSA®), and radiotherapy followed by surgical resection; a phase II study of radiation therapy, paclitaxel poliglumex and carboplatin in stage III non-small cell lung cancer; and a phase I/II open-label dose escalation study of anti-CTLA4 antibody with radiation for metastatic hormone refractory prostate cancer.
Forth, Dr. Gottschalk is involved with several RTOG (Radiation Therapy Oncology Group) studies. These have included several prostate cancer trials that investigate: high-dose vs standard-dose readiation for intermediate-risk prostate cancer; brachytherapy vs external-beam radiation plus brachytherapy for intermediate-risk prostate cancer; and standard fractionation vs hypofractionation for low-risk prostate cancer. Finally, as Director of the CyberKnife Radiosurgery Program Dr. Gottschalk oversees several of the stereotactic body radiosugery (SBRT) trials for lung and prostate cancer. He has a particular interest in the use of CyberKnife SBRT for the treatment of prostate cancer, kidney cancer, and lung cancer.
Clinical Trials
- Study ID: NCT01434290Start Date: Sep 2011Estimated Completion Date: Jan 0001Condition(s): Prostate Cancer, Cancer, General, Radiation Toxicity, Sexual Dysfunction
- Study ID: NCT00750269Start Date: Feb 2009Estimated Completion Date: Jan 0001Condition(s): Lung Cancer, Non-Small Cell Lung Cancer
Publications
MOST RECENT PUBLICATIONS FROM A TOTAL OF 118
- Hanson SM, Scholüke J, Liewald J, Sharma R, Ruse C, Engel M, Schüler C, Klaus A, Arghittu S, Baumbach F, Seidenthal M, Dill H, Hummer G, Gottschalk A. Structure-function analysis suggests that the photoreceptor LITE-1 is a light-activated ion channel. Curr Biol. 2023 08 21; 33(16):3423-3435.e5. View in PubMed
- Shee K, de la Calle CM, Chang AJ, Wong AC, Feng FY, Gottschalk AR, Carroll PR, Nguyen HG. Addition of Enzalutamide to Leuprolide and Definitive Radiation Therapy Is Tolerable and Effective in High-Risk Localized or Regional Nonmetastatic Prostate Cancer: Results From a Phase 2 Trial. Adv Radiat Oncol. 2022 Sep-Oct; 7(5):100941. View in PubMed
- Chen WC, Li Y, Lazar A, Altun A, Descovich M, Nano T, Ziemer B, Sudhyadhom A, Cunha A, Thomas H, Gottschalk A, Hsu IC, Roach M. Stereotactic Body Radiation Therapy and High-Dose-Rate Brachytherapy Boost in Combination With Intensity Modulated Radiation Therapy for Localized Prostate Cancer: A Single-Institution Propensity Score Matched Analysis. Int J Radiat Oncol Biol Phys. 2021 06 01; 110(2):429-437. View in PubMed
- Wu SY, Lazar AA, Gubens MA, Blakely CM, Gottschalk AR, Jablons DM, Jahan TM, Wang VEH, Dunbar TL, Wong ML, Chan JW, Guthrie W, Belkora J, Yom SS. Evaluation of a National Comprehensive Cancer Network Guidelines-Based Decision Support Tool in Patients With Non-Small Cell Lung Cancer: A Nonrandomized Clinical Trial. JAMA Netw Open. 2020 09 01; 3(9):e209750. View in PubMed
- Chen WC, Baal JD, Baal U, Pai J, Gottschalk A, Boreta L, Braunstein SE, Raleigh DR. Stereotactic Body Radiation Therapy of Adrenal Metastases: A Pooled Meta-Analysis and Systematic Review of 39 Studies with 1006 Patients. Int J Radiat Oncol Biol Phys. 2020 05 01; 107(1):48-61. View in PubMed
- View All Publications
In the News
- UCSF Thoracic Oncology Program - - July 28, 2016While traditionally, standard treatment has consisted of surgery and radiation, sarcoma programs at higher volume centers of excellence such as UCSF, have found, with accumulated experience, that adding chemotherapy to surgery and radiation can be quite effective. Experienced Team of Specialists At UCSF Medical Center, sarcoma patients are treated by a highly experienced multidisciplinary team that includes orthopedic and general surgeons; medical and radiation oncologists; pathologists, [...]
